China NMPA Drug Inspection - Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. - Fosfomycin calcium granules
China NMPA drug inspection for Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. published May 16, 2013. Drug: Fosfomycin calcium granules. China's State Food and Drug Administration (SFDA) issued a Drug Quality Announcement on May 16, 2013, detailing the resu
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. published May 16, 2013. Drug: Fosfomycin calcium granules. China's State Food and Drug Administration (SFDA) issued a Drug Quality Announcement on May 16, 2013, detailing the resu
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox